BRAF and melanoma: In the Kaplan–Meier survival analysis, both melanoma-specific survival (MSS) and distant metastasis-free survival (DMFS) were significantly longer in patients with BRAF WT primary melanomas showing miR-125b (MSS rate = 100% vs. 48.98%, p-value = 0.0098 and DMFS rate = 88.89% vs. 48.98%, p-value = 0.0327), miR-200c (MSS rate = 100% vs. 48.98%, p-value = 0.0098 and DMFS rate = 100% vs. 40.82%, p-value = 0.0044) and miR-205 (MSS rate = 100% vs. 44.81%, p-value 0.0044 and DMFS rate = 100% vs. 35.89%, p-value = 0.0016) expression levels above the median.